These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17179168)

  • 1. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin).
    Manzano RP; Peyman GA; Khan P; Carvounis PE; Kivilcim M; Ren M; Lake JC; Chévez-Barrios P
    Br J Ophthalmol; 2007 Jun; 91(6):804-7. PubMed ID: 17179168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibitory effects of trastuzumab on corneal neovascularization.
    Güler M; Yilmaz T; Ozercan I; Elkiran T
    Am J Ophthalmol; 2009 Apr; 147(4):703-708.e2. PubMed ID: 19054498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.
    Hashemian MN; Moghimi S; Kiumehr S; Riazi M; Amoli FA
    Ophthalmic Res; 2009; 42(2):90-5. PubMed ID: 19546599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).
    Kim TI; Kim SW; Kim S; Kim T; Kim EK
    Cornea; 2008 Apr; 27(3):349-52. PubMed ID: 18362666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
    Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.
    Hurmeric V; Mumcuoglu T; Erdurman C; Kurt B; Dagli O; Durukan AH
    Cornea; 2008 Apr; 27(3):357-62. PubMed ID: 18362668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization.
    Habot-Wilner Z; Barequet IS; Ivanir Y; Moisseiev J; Rosner M
    Acta Ophthalmol; 2010 Dec; 88(8):862-7. PubMed ID: 19549103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.
    Aydin E; Kivilcim M; Peyman GA; Esfahani MR; Kazi AA; Sanders DR
    Cornea; 2008 May; 27(4):446-53. PubMed ID: 18434849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.
    Hashemian MN; Z-Mehrjardi H; Moghimi S; Tahvildari M; Mojazi-Amiri H
    Ophthalmic Res; 2011; 46(1):50-4. PubMed ID: 21212709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea.
    Barros LF; Belfort R
    An Acad Bras Cienc; 2007 Sep; 79(3):389-94. PubMed ID: 17768531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.
    Papathanassiou M; Theodossiadis PG; Liarakos VS; Rouvas A; Giamarellos-Bourboulis EJ; Vergados IA
    Am J Ophthalmol; 2008 Mar; 145(3):424-431. PubMed ID: 18207123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis.
    Hosseini H; Nejabat M; Mehryar M; Yazdchi T; Sedaghat A; Noori F
    Clin Exp Ophthalmol; 2007 Nov; 35(8):745-8. PubMed ID: 17997779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.
    Ozdemir O; Altintas O; Altintas L; Yildiz DK; Sener E; Caglar Y
    Can J Ophthalmol; 2013 Apr; 48(2):115-20. PubMed ID: 23561605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model.
    Riazi-Esfahani M; Peyman GA; Aydin E; Kazi AA; Kivilcim M; Sanders DR
    Cornea; 2006 Aug; 25(7):801-5. PubMed ID: 17068457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits.
    Kang S; Chung SK
    Cornea; 2010 Feb; 29(2):192-6. PubMed ID: 20098156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.
    Sener E; Yuksel N; Yildiz DK; Yilmaz B; Ozdemir O; Caglar Y; Degirmenci E
    Curr Eye Res; 2011 Nov; 36(11):1005-13. PubMed ID: 21999227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn.
    Yoeruek E; Ziemssen F; Henke-Fahle S; Tatar O; Tura A; Grisanti S; Bartz-Schmidt KU; Szurman P;
    Acta Ophthalmol; 2008 May; 86(3):322-8. PubMed ID: 17995975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.
    Pérez-Santonja JJ; Campos-Mollo E; Lledó-Riquelme M; Javaloy J; Alió JL
    Am J Ophthalmol; 2010 Oct; 150(4):519-528.e1. PubMed ID: 20591397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.